Sodium oligomannate
Phase 3Small molecule
Sodium oligomannate is one of 79 small molecule programs targeting Alzheimer's Disease. It is currently in Phase 3.
2
Indications
3
Total Trials
3
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
228 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Savaysa
Daiichi SankyoPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Rilutek
AAzurity Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Becotatug Vedotin
FFudan University
Phase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Raphamin
MMateria Medica Holding
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Long-term Efficacy and Safety Study of GV-971
Active, not recruiting·GGreen Valley (Shanghai) Pharmaceuticals Co., Ltd.·Phase 4·NCT05181475·800 enrolled
Unspecified1 trial
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
Active, not recruiting·GGreen Valley (Shanghai) Pharmaceuticals Co., Ltd.·Phase 4·NCT05058040·2,500 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sodium oligomannate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details